Supplementary Figure 4: Characterization of immune infiltrates in B16-OVA melanomas upon UCP2 induction.

a, b, Percentage (a) and absolute number of NK cells per gram of tumor (b) from indicated tumor-bearing mice as illustrated in Figs. 3a. (a, 3F, n = 10; 3F+Dox, n = 13; 3F-UCP2, n = 11; 3F-UCP2+Dox, n = 9. b, 3F, n = 10; 3F+Dox, n = 13; 3F-UCP2, n = 10; 3F-UCP2+Dox, n = 9). c, d, Percentage (c) and absolute number of CD4⁺ T cells per gram of tumor (d) from indicated tumor-bearing mice. (c, 3F, n = 11); 3F+Dox, n = 13; 3F-UCP2, n = 11; 3F-UCP2+Dox, n = 9. d, 3F, n = 9; 3F+Dox, n = 12; 3F-UCP2, n = 10; 3F-UCP2+Dox, n = 9). e, f, Percentage of regulatory T cells (Tregs) (e) and B cells (f) among CD45⁺ cells in melanomas from indicated tumor-bearing mice. (e, 3F, n = 11; 3F+Dox, n = 13; 3F-UCP2, n = 11; 3F-UCP2+Dox, n = 9. f, 3F, n = 8; 3F+Dox, n = 9; 3F-UCP2, n = 7; 3F-UCP2+Dox, n = 5). g, h, Percentage of IFN-γ-producing (g) and TNF producing (h) CD8⁺ T cells among total tumor-infiltrating CD8⁺ T cells from indicated mice. (g, 3F, n = 15; 3F+Dox, n = 11; 3F-UCP2, n = 17; 3F-UCP2+Dox, n = 17. h, 3F, n = 8; 3F+Dox, n = 8; 3F-UCP2, n = 8; 3F-UCP2+Dox, n = 7). i, Quantitative result of MHC-I expression in indicated B16-OVA cell lines treated with or without Dox. (n = 9 in each group). j, Quantitative result of OT-I T cells interacting with indicated B16-OVA cell lines treated with control vehicle or Dox. (n = 6 in each group). k, Quantitative result (left panel) and representative FACS plot (right panel) of PD-L1 expression in B16-OVA 3F-UCP2 cell lines treated with control vehicle or Dox. (n = 9 in each group). l, Survival percentage of indicated B16 melanoma cells in the in vitro effector:target cell titration assay. (n = 9 in each group). All data are mean±s.e.m. Data are cumulative results from at least three independent experiments. n.s., not significant; unpaired, two-tailed Student’s t-test.